Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

被引:50
|
作者
Esquirol, Albert [1 ]
Pascual, Maria Jesus [2 ]
Kwon, Mi [3 ]
Perez, Ariadna [4 ]
Parody, Rocio [5 ]
Ferra, Christelle [6 ]
Garcia Cadenas, Irene [1 ]
Herruzo, Beatriz [2 ]
Dorado, Nieves [3 ]
Hernani, Rafael [4 ]
Sanchez-Ortega, Isabel [5 ]
Torrent, Anna [6 ]
Sierra, Jorge [1 ]
Martino, Rodrigo [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, IIB St Pau & Jose Carreras Leukemia Res Inst, Hematol Dept, Barcelona, Spain
[2] Hosp Reg Univ, Hematol Dept, Malaga, Spain
[3] Hosp Gregorio Maranon, Hematol Dept, Madrid, Spain
[4] Hosp Clin Univ, Hematol Dept, Madrid, Spain
[5] Bellvitge Hosp, Hematol Dept, Barcelona, Spain
[6] Hosp Badalona Germans Trias & Pujol, Hematol Dept, Badalona, Spain
关键词
BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; RISK-FACTORS; HEMATOLOGIC MALIGNANCIES; HEMORRHAGIC CYSTITIS; ACUTE-LEUKEMIA; BACTEREMIA; OUTCOMES; DONORS; ADULTS;
D O I
10.1038/s41409-021-01328-4
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Severe infections and their attributable mortality are major complications in recipients of allogeneic hematopoietic stem cell transplantation (alloSCT). We herein report 236 adult patients who received haploSCT with PTCy. The median follow-up for survivors was 37 months. The overall incidence of bloodstream infections by gram-positive and gram-negative bacteria at 37 months was 51% and 46%, respectively. The incidence of cytomegalovirus infection was 69%, while Epstein Barr virus infections occurred in 10% of patients and hemorrhagic cystitis in 35% of cases. Invasive fungal infections occurred in 11% at 17 months. The 3-year incidence of infection-related mortality was 19%. The median interval from transplant to IRM was 3 months (range 1-30), 53% of IRM occurred >100 days post-haploSCT. Risk factors for IRM included age >50 years, lymphoid malignancy, and developing grade III-IV acute GvHD. Bacterial infections were the most common causes of IRM (51%), mainly due to gram-negative bacilli BSI. In conclusion, severe infections are the most common causes of NRM after haploSCT with PTCy, with a reemergence of gram-negative bacilli as the most lethal pathogens. More studies focusing on the severe infections after haploSCT with PTCy and differences with other types of alloSCT in adults are clearly warranted.
引用
收藏
页码:2432 / 2444
页数:13
相关论文
共 50 条
  • [1] Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
    Mohty, Razan
    Al Kadhimi, Zaid
    Kharfan-Dabaja, Mohamed
    HEMATOLOGY, 2024, 29 (01)
  • [2] Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation
    Dulery, Remy
    Malard, Florent
    Brissot, Eolia
    Banet, Anne
    Sestili, Simona
    Belhocine, Ramdane
    Calabro, Martina
    van de Wyngaert, Zoe
    Bonnin, Agnes
    Ledraa, Tounes
    Legrand, Ollivier
    Labopin, Myriam
    Capderou, Elodie
    Cohen, Ariel
    Ederhy, Stephane
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2023, 58 (11) : 1215 - 1222
  • [3] Haploidentical Stem Cell Transplantation With Post-transplant Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective
    Sharma, Anil
    Rastogi, Neha
    Chatterjee, Goutomi
    Kapoor, Rohit
    Nivargi, Sagar
    Yadav, Satya P.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (07) : E1033 - E1036
  • [4] Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies
    Dulery, Remy
    Goudet, Claire
    Mannina, Daniele
    Bianchessi, Antonio
    Granata, Angela
    Harbi, Samia
    Maisano, Valerio
    Chabannon, Christian
    Malard, Florent
    Brissot, Eolia
    Sestili, Simona
    Banet, Anne
    van de Wyngaert, Zoe
    Belhocine, Ramdane
    Ederhy, Stephane
    Castagna, Luca
    Bramanti, Stefania
    Blaise, Didier
    Mohty, Mohamad
    Fuerst, Sabine
    Devillier, Raynier
    BONE MARROW TRANSPLANTATION, 2023, 58 (04) : 386 - 392
  • [5] Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immunodeficiencies and Inherited Disorders in Children
    Neven, Benedicte
    Diana, Jean-Sebastien
    Castelle, Martin
    Magnani, Alessandra
    Rosain, Jeremie
    Touzot, Fabien
    Moreira, Baptiste
    Fremond, Marie-Louise
    Briand, Coralie
    Bendavid, Matthieu
    Levy, Romain
    Morelle, Guillaume
    Vincent, Marc
    Magrin, Elsa
    Bourget, Philippe
    Chatenoud, Lucienne
    Picard, Capucine
    Fischer, Alain
    Moshous, Despina
    Blanche, Stephane
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (07) : 1363 - 1373
  • [6] Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: A single-center study
    Yesilipek, M. Akif
    Uygun, Vedat
    Karasu, Gulsun
    Daloglu, Hayriye
    Dincer, Zeynep
    PEDIATRIC TRANSPLANTATION, 2016, 20 (03) : 417 - 423
  • [7] Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation
    Hong, Kyung Taek
    Bae, Sungyeun
    Sunwoo, Yoon
    Lee, Juyeon
    Park, Hyun Jin
    Kim, Bo Kyung
    Choi, Jung Yoon
    Cho, Joo-Youn
    Yu, Kyung-Sang
    Oh, Jaeseong
    Kang, Hyoung Jin
    BIOMARKER RESEARCH, 2025, 13 (01)
  • [9] Outpatient haploidentical hematopoietic stem cell transplant using post-transplant cyclophosphamide and incidence of hemorrhagic cystitis
    Gutierrez-Aguirre, Cesar Homero
    Esparza-Sandoval, Alejandra Celina
    Palomares-Leal, Alain
    Jaime-Perez, Jose Carlos
    Gomez-Almaguer, David
    Cantu-Rodriguez, Olga Graciela
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2022, 44 (02) : 163 - 168
  • [10] Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Safe and Feasible
    Colunga-Pedraza, Perla R.
    Gomez-De Leon, Andres
    Saul Rodriguez-Roque, Carlos
    Morcos-Sandino, Michelle
    Colunga-Pedraza, Julia E.
    Graciela Cantu-Rodriguez, Olga
    Homero Gutierrez-Aguirre, Cesar
    Gomez-Almaguer, David
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 259.e1 - 259.e6